Plasma Protease C1-Inhibitor Market Expected to Reach $7.96 Billion by 2032, Growing at a CAGR of 9.6%

The global plasma protease C1-inhibitor market size is expected to reach USD 7.96 billion by 2032, exhibiting a CAGR of 9.6% during the forecast period.

The Plasma Protease C1-Inhibitor Market refers to the market for products that contain plasma-derived or recombinant C1-inhibitors used in the treatment of various conditions, especially hereditary angioedema (HAE). The C1-inhibitor is a crucial protein in the human body that plays a key role in regulating the complement and contact systems. Deficiencies in C1-inhibitor can result in a range of disorders, most notably HAE, which causes episodes of severe swelling in various parts of the body.

Market’s Growth Drivers

1. Increasing Prevalence of Hereditary Angioedema (HAE):
   • HAE is a rare, genetic disorder that leads to recurrent episodes of swelling in various parts of the body, including the extremities, gastrointestinal tract, and upper respiratory tract. It is caused by a deficiency of functional C1-inhibitor. The rising diagnosis and awareness of HAE, particularly in developing regions, are propelling demand for C1-inhibitor therapies.
2. Advances in Plasma-Derived and Recombinant Therapies:
   • Technological advancements in the production of both plasma-derived and recombinant C1-inhibitors are enabling more effective treatment options. Recombinant C1-inhibitors, such as ruconest and eculizumab, offer the advantage of being derived from non-human sources, reducing the risk of viral transmission associated with plasma-derived therapies.
3. Growing Awareness of Rare Diseases:
   • There has been a global increase in awareness surrounding rare diseases, including HAE. Governments, patient organizations, and healthcare providers are working towards better diagnosis and treatment options for rare diseases, thereby driving the demand for C1-inhibitor therapies.

Download Free Sample PDF Copy of the Report:

https://www.polarismarketresearch.com/industry-analysis/plasma-protease-c1-inhibitor-market/request-for-sample

List of Key Companies in Plasma Protease C1-inhibitor Market

• BioCryst Pharmaceuticals, Inc.
• CENTOGENE N.V.
• CSL
• Fresenius Kabi
• Ionis Pharmaceuticals, Inc.
• KalVista Pharmaceuticals
• Pharming
• Sanquin
• Shire plc

Key Trends in the Market

1. Shift Toward Recombinant C1-Inhibitor Products:
   • The shift from plasma-derived to recombinant C1-inhibitors is a major trend. Recombinant products are gaining popularity because they are considered safer and more efficient, eliminating the risk of contamination from plasma. These therapies also offer greater consistency in terms of product quality.
2. Home Administration and Patient Convenience:
   • There is a growing trend toward treatments that allow patients to administer C1-inhibitors at home, offering greater convenience and reducing hospital visits. Self-administration options are becoming a key factor in patient satisfaction and adherence to treatment regimens.
3. Increased Focus on Long-Term Management:
   • As more patients are diagnosed with HAE, there is a growing emphasis on long-term management strategies to control symptoms and prevent acute attacks. This trend is driving demand for long-acting C1-inhibitor treatments that require fewer infusions over time.

𝐑𝐞𝐠𝐢𝐨𝐧𝐚𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬:

The regional analysis section sheds light on the industry trends and [KEYWORD] market dynamics across different geographic regions. It examines all the major factors shaping the market behavior globally. These include economic conditions, regulatory frameworks, and cultural influences. Besides, the impact of consumer preferences on market growth has been examined in the report. Regional analysis helps stakeholders identify market opportunities and challenges at the regional level. Also, regional analysis enables businesses to devise strategies to capitalize on specific industry trends and conditions. Along with all the major regions, an in-depth analysis of all the major sub-regions has been provided in the study.

By Drug Class Outlook

• C1-inhibitors
  • C1-esterase Inhibitor
  • Recombinant Inhibitor
• Kallikrein Inhibitor
• Selective Bradykinin B2 Receptor Antagonist

By Dosage Form Outlook

• Lyphophlised
• Injectables

By Distribution Channel Outlook

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Plasma Protease C1-inhibitor Industry Developments

• May 2024: BioCryst Pharmaceuticals, Inc. presented new real-world evidence at ISPOR 2024 showing significant reductions in healthcare resource utilization among US patients with hereditary angioedema (HAE) following initiation of ORLADEYO (berotralstat).
• May 2023: KalVista Pharmaceuticals presented data at the 13th C1-inhibitor Deficiency & Angioedema Workshop, highlighting insights on sebetralstat’s short-term prophylaxis regimen and patient preferences for oral on-demand treatments in hereditary angioedema (HAE).
• December 2022: Takeda launched CINRYZE in India as the first C1 esterase inhibitor for prophylaxis in hereditary angioedema patients, offering both acute attack treatment and prevention options.

The Plasma Protease C1-Inhibitor Market is experiencing robust growth due to the increasing prevalence of hereditary angioedema, advancements in plasma-derived and recombinant C1-inhibitor therapies, and a greater focus on rare diseases. As new treatments become available and healthcare systems evolve, the market is expected to continue expanding. Innovations in biotechnology, patient-centered care models, and collaborations between pharmaceutical companies and research institutions will drive the future of the market, making C1-inhibitor therapies more effective, accessible, and affordable for patients worldwide.